Candel Therapeutics, Inc. (CADL)

Candel Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.13	0.13	0.13
Cost of Revenue	18.23	23.59	20.35	14.59	-
Gross Profit	-18.23	-23.59	-20.22	-14.47	0.13
Selling, General & Admin	14.4	14.41	14.5	11.26	5.99
Research & Development	-	-	-	-	7.94
Operating Expenses	14.4	14.41	14.5	11.26	13.94
Operating Income	-32.63	-38	-34.72	-25.73	-13.81
Interest Expense	-2.09	-2.6	-1.71	-0.05	-
Interest & Investment Income	1.09	2.08	1.22	-	0.11
Other Non Operating Income (Expenses)	-20.8	0.97	16.42	-10.81	-3.98
EBT Excluding Unusual Items	-54.44	-37.55	-18.79	-36.59	-17.68
Merger & Restructuring Charges	-0.7	-	-	-	-
Asset Writedown	-0.04	-0.39	-	-	-
Other Unusual Items	-	-	-	0.46	-
Pretax Income	-55.18	-37.94	-18.79	-36.12	-17.68
Net Income	-55.18	-37.94	-18.79	-36.12	-17.68
Net Income to Common	-55.18	-37.94	-18.79	-36.12	-17.68
Shares Outstanding (Basic)	32	29	29	19	12
Shares Outstanding (Diluted)	32	29	29	19	12
Shares Change (YoY)	9.47%	0.39%	52.72%	62.49%	0.70%
EPS (Basic)	-1.74	-1.31	-0.65	-1.91	-1.52
EPS (Diluted)	-1.74	-1.31	-0.65	-1.91	-1.52
Free Cash Flow	-27.04	-34.7	-32.72	-24.05	-10.55
Free Cash Flow Per Share	-0.85	-1.20	-1.14	-1.27	-0.91
Gross Margin	-	-	-	-	100.00%
Operating Margin	-	-	-27777.60%	-20580.80%	-11048.00%
Profit Margin	-	-	-15035.20%	-28899.20%	-14144.00%
Free Cash Flow Margin	-	-	-26172.80%	-19242.40%	-8437.60%
EBITDA	-31.64	-37.04	-33.94	-25.49	-13.72
D&A For EBITDA	0.99	0.96	0.78	0.23	0.09
EBIT	-32.63	-38	-34.72	-25.73	-13.81

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q